Initiation, progression and remission of diabetic nephropathy

Danish Medical Bulletin

Volumn 52, Issue 4, 2005, Pages 119-142

  Hovind, Peter ^a,b  

^a STENO DIABETES CENTER   (Denmark)

^b NONE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GROWTH HORMONE; GROWTH HORMONE ANTAGONIST; HOMOCYSTEINE; HORMONE ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOPROLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; SIMVASTATIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CIGARETTE SMOKING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; GENETIC SUSCEPTIBILITY; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INCIDENCE; KIDNEY BLOOD FLOW; MICROALBUMINURIA; PATHOGENESIS; PROTEIN INTAKE; REMISSION; REVIEW; RISK ASSESSMENT;

DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS;

EID: 33646143980     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Review

References (294)

1. National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System: USRDS 2001 Annual Data Report, Bethesda. The National Institute of Health 2001.
2. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501.
3. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in Type 1 diabetes. Am.J.Med. 1985;78:785-94.
4. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T. Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diab 1987;36:205-9.
5. Kussman MJ, Goldstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA 1976;236:1861-3.
6. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H. Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. Br.Med.J. 1996;313:779-84.
7. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In Brenner BM, ed. The Kidney, pp 1777-818. WB Saunders, 2004.
8. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest. 1985;9:85-95.
9. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa Ph et al. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995;346:1080-4.
10. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H-H. Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br.Med.J. 1999;319:24-5.
11. Parving H-H, Andersen AR, Smidt UM, Svendsen PAa. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;i:1175-9.
12. Watkins PJ, Blainey JD, Brewer DB, Fitzgerald MG, Malins JM, O'Sullivan DJ et al. The natural history of diabetic renal disease. A follow-up study of series of renal biopsies. Q J Med 1972;41:437-56.
13. Austin SM, Lieberman JS, Newton LD, Mejia M, Peters WA, Myers BD. Slope of serial glomerular filtration rate and the progression of diabetic glomerular disease. J Am Soc Nephrol 1993;3:1358-70.
14. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N et al. Remission of nephrotic-range proteinuria in type I diabetes. Kidney Int. 1994;46:1688-93.
15. Bangstad H-J, Østerby R, Dahl-Jørgensen K, Berg K, Hartmann A, Nyberg G et al. Early glomerulopathy is present in young, Type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36:523-9.
16. Bangstad H-L, Østerby R, Dahl-Jørgensen K, Berg K, Hartmann A, Hanssen KF. Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 1994;37:483-90.
17. Østerby R, Gall M-A, Schmitz A, Nielsen FS, Nyberg G, Parving H-H. Glomerular structure and function in proteinuric Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:1064-70.
18. Rossing P. Doubling of serum creatinine: is it sensitive and relevant? Nephrol.Dial.Transplant. 1998;13:244-6.
19. Mogensen CE. Angiotensin converting enzyme inhibitors and diabetic nephropathy. Br.Med.J. 1992;304:327-8.
20. Levey AS, Gassman J, Hall PM, Walker WG. Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. J Am Soc Nephrol 1991;1:1087-94.
21. Parving H-H. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment. Diabetologia 1998;41:745-59.
22. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-6.
23. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int. 1994;45 (suppl. 45):S145-S149.
24. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int. 1994;45 (Suppl. 45):SI74-Sl78.
25. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. Journal of Gerontology 1976;31:155-63.
26. Bröchner-Mortensen J. A simple method for the determination of glomerular filtration rate. Scand.J.Clin.Lab.Invest. 1972;30:271-4.
27. 51 Cr-EDTA. Scand.J.Clin.Lab.Invest. 1969;23: 301-5.
28. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Progression of diabetic nephropathy. Kidney Int. 2001;59:702-9.
29. Hovind, P., Tarnow, L., Rossing, P., Carstensen, B., and Parving, H-H. Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney International 2004;30: 1180-1186.
30. Rossing P, Rossing K, Jacobsen P, Parving H-H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diab 1995;44:739-43.
31. Rossing K, Jacobsen P, Rossing P, Lauritzen E, Lund-Andersen H, Parving H-H. Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy. Diabetes Care 1998;21:2007-15.
32. Mogensen CE. Renal function changes in diabetes. Diab 1976;25:872-9.
33. Christiansen JS, Frandsen M, Parving H-H. The effect of intravenous insulin infusion on kidney function in insuln-dependent diabetes mellitus. Diabetologia 1981;20:199-204.
34. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am.J.Med. 1982;72:375-80.
35. Mogensen CE. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand.J.Clin.Lab.Invest. 1986;46:201-6.
36. Lervang H-H, Jensen S, Bröchner-Mortensen J, Ditzel J. Early glomerular hyperfiltration and the development of late rephropathy in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1988;31:723-9.
37. Jones SL, Wiseman MJ, Viberti GC. Glomerular hyperfiltration as a risk factor for diabetic nephropathy: five year report of a prospective study. Diabetologia 1991;34:59-60.
38. Rudberg S, Persson B, Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy - an 8-year prospective study. Kidney Int. 1992;41:822-8.
39. Østerby R,.Gundersen HJG. Glomerular size and structure in diabetes mellitus. I. Early abnormalities. Diabetologia 1975;11:225-9.
40. Kimmelstiel P,.Wilson C. Intercapillary lesions in the glomeruli of the kidney. American Journal of Pathology 1936;12:83-96.
41. Parving H-H, Oxenbøll. B, Svendsen PAa, Christiansen JS, Andersen AR. Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol. 1982;100:550-5.
42. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;i:1430-2.
43. Mogensen CE,.Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
44. Mathiesen ER, Oxenbøll B, Johansen K, Svendsen PAa, Deckert T. Incipient nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1984;26:406-10.
45. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all type 1 diabetic microalbuminuric patients receive ACE inhibitors? A meta-regression analysis. Ann Intern Med 2001;134:370-9.
46. Hansen HP, Lund SS, Rossing P, Tarnow L, Nielsen FS, Jensen T et al. Preventing diabetic nephropathy: an audit. Scand.J.Clin.Lab Invest 2001;61:471-7.
47. Myers BD, Winetz JA, Chui F, Michaels AS. Mechanisms of proteinuria in diabetic nephropathy: A study of glomerular barrier function. Kidney Int. 1982;21:633-41.
48. Tomlanovich S, Deen WM, Jones III HW, Schwartz HC, Myers BD. Functional nature of glomerular injury in progressive diabetic glomerulopathy. Diab 1987;36:556-65.
49. Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand.J. Clin.Lab.Invest. 1976;36:383-8.
50. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 1981;20:457-61.
51. Viberti GC, Bilous RW, Mackintosh D, Keen H. Monitoring glomerular function in diabetic nephropathy. Am.J.Med. 1983;74:256-64.
52. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 1981;19:410-5.
53. Mauer SM, Steffes MW, Ellis EN, Sutherland DER, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-55.
54. Østerby R, Parving H-H, Hommel E, Jørgensen HE, Løkkegaard H. Glomerular structure and function in diabetic nephropathy - early to advanced stages. Diab 1990;39:1057-63.
55. Lundbæk K. Diabetic angiopathy. A specific vascular disease. Lancet 1954;i:377-9.
56. Kofoed-Enevoldsen A, Jensen T, Borch-Johnsen K, Deckert T. Incidence of retinopathy in type 1 (insulin-dependent) diabetes: association with clinical nephropathy. J Diabetes Complications 1987;1:96-9.
57. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiology study of diabetic retinopathy: proteinuria and retinopathy in a population of diabetic persons diagnosed prior to 30 years of age. In Friedman EA, L'Esperance FA, eds. Diabetic renal-retinal syndrome, pp 245-64. New York. Grune & Stratton, 1986.
58. Borch-Johnsen K,.Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br.Med.J. 1987;294:1651-4.
59. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989;32:219-26.
60. Krolewski AS, Warram JH, Rand LI, Christlieb AR, Busick EJ, Kahn CR. Risk of proliferative diabetic retinopathy in juvenile-onset type 1 diabetes: a 40-yr follow-up study. Diabetes Care 1986;9:443-52.
61. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg B, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-8.
62. Bojestig M, Arnqvist HJ, Karlberg BE, Ludvigsson J. Unchanged incidence of severe retinopathy in a population of Type 1 diabetic patients with marked reduction of nephropathy. Diabet.Med 1998;15:863-9.
63. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-64.
64. Microalbuminuria Collaborative Study Group UK. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Br.Med.J. 1993;306:1235-9.
65. Almdal T, Nørgaard K, Feldt-Rasmussen B, Deckert T. The predictive value of microalbuminuria in IDDM. Diabetes Care 1994; 17:120-5.
66. Muhlhauser I, Bender R, Bott U, Jorgens V, Grusser M, Wagener W et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet.Med. 1996;13:536-43.
67. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 1998;105:1801-15.
68. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
69. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-67.
70. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. Br.Med.J. 1991;303:81-7.
71. Viberti GC, Mogensen CE, Groop L, Pauls JF, the European Microalbuminuria Captopril Study Group. Effect of Captoptil on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994;271:275-9.
72. Laffel LMB, McGill JB, Gans JD. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am.J.Med. 1995;99:497-504.
73. Chaturvedi N, Sjolie A-K, Stephenson JM, Abrahamian H, Keipes M, Castellarin A et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28-31.
74. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br.Med.J. 1988;297:1086-91.
75. Parving H-H. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus. Diabetes Care 1991; 14:260-9.
76. American Diabetes Association. Treatment of Hypertension in Diabetes. Diabetes Care 1993;16:1394-401.
77. Christiansen JS. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1978;1:146-9.
78. Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T. Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med.Scand. 1984;215:63-8.
79. Nordén G,.Nyberg G. Smoking and diabetic nephropathy. Acta Med. Scand. 1984;215:257-61.
80. Mühlhauser I, Sawicki PT, Berger M. Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1986;29:500-2.
81. Chase HP, Garg SK, Marshall G, Berg CL, Harris S, Jackson WE et al. Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 1991;265:614-7.
82. Chaturvedi N, Stephenson J, Fuller JH, The Eurodiab IDDM Complications study. The relationship between smoking and microvascular complications in the Eurodiab IDDM Complication Study. Diabetes Care 1995;18:785-92.
83. Rossing P, Hougaard P, Parving H-H. Risk factors for development of incipient and overt diabetic nephropathy in Type 1 diabetic patients. Diabetes Care 2002;25:859-64.
84. Nielsen PE, Falk J, Danielsen US. [Smoking habits and attitude toward tobacco use among health professionals in Denmark in 1996]. Ugeskr Laeger 2000;162:4140-4.
85. Nishimura R, Dorman JS, Bosnyak Z, Tajima N, Becker DJ, Orchard TJ. Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry. Am.J.Kidney Dis. 2003;42:117-24.
86. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE. Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes. Br.Med.J. 1993;306:1722-5.
87. Kiberd BA,.Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. Br.Med.J. 1995;311: 1595-9.
88. Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A, Singh G et al. The cost-effectiveness of different management strategies for type I diabetes: a Swiss perspective. Diabetologia 2000;43:13-26.
89. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, torp I et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. Br.Med.J. 2004;328:1105-8. Long version: DOI: 10.1136/bmj.38070.450891.FE.
90. Mathiesen ER, Rønn B, Jensen T, Storm B, Deckert T. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diab 1990;39:245-9.
91. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int. 1995;47:1703-20.
92. The microalbuminuria Collaborative study group. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven-year prospective study. Diabetic Med. 1999; 16:918-25.
93. Schultz CJ, Neil H, Dalton R, Dunger D. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after diagnosis oftype 1 diabetes. Diabetes Care 2000;23:1811-5.
94. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N.Engl.J.Med. 2003;348:101-8.
95. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 1989;321:1074-9.
96. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease: Evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-5.
97. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1990; 33:438-43.
98. Borch-Johnsen K, Nørgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T et al. Is diabetic nephropathy an inherited complication? Kidney Int. 1992;41:719-22.
99. Earle K, Walker J, Hill C, Viberti GC. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992;326:673-7.
100. The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control adn complications trial. Diab 1997;46:1829-39.
101. Tarnow L, Rossing P, Nielsen FS, Fagerudd JA, Poirier O, Parving H-H. Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000;23:30-3.
102. Tarnow L. Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors. Dan.Med.Bull. 2002;49:19-42.
103. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/ deletion polymorphism of the human angiotensin converting enzyme gene (DCP 1) (dipeptidyl-carboxy peptidose 1). Nucleic Acids Res 1992;20:1433.
104. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J.Clin.Invest 1997;99:1585-95.
105. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. J.Am.Soc.Nephrol. 2001;12:541-9.
106. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diab 1995;44:489-94.
107. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/ deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998;13:1125-30.
108. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988;82:735-8.
109. Meraji S, Jayakody L, Senaratne MP, Thompson ABR, Kappagoda T. Endothelium-dependent relaxation in aorta from diabetic rats. Diab 1987;36:978-81.
110. Ayo SH, Radnik RA, Glass WF, Garoni JA, Rampt ER, Appling DR et al. Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol 1991;260:F185-F191.
111. Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture: delayed replication, disturbed cell cycle, and accelerated death. Diab 1985;34:621-7.
112. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
113. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch.Ophthalmol. 1990;108:1234-44.
114. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21.
115. Cohen MP, Ziyadeh FN. Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int. 1994;45:475-84.
116. Schajkwijk CG, Ligtvoet N, Twaalfhoven H, Jager A, Blaauwgeers HGT, Schlingemann RO et al. Amadori albumin in type 1 diabetic patients - correlation with markers of endothelial dysfunction, association with diabetic nephropathy, and localization in retinal capillaries. Diab 1999;48:2446-53.
117. Soules-Liparota T, Cooper ME, Papazoglou D, Clarke B, Jerums F. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diab 1991;40:1328-34.
118. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001;44:108-14.
119. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-72.
120. Koya D,. King GL. Protein Kinase C activation and the development of diabetic complications. Diab 1998;47:859-66.
121. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diab 1997;46:1497-503.
122. Koya D, Jirousek MR, Lin Y-W, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-26.
123. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 1996;272:728-31.
124. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv.Ophthalmol. 2002;47 Suppl 2:S263-S269.
125. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc.Natl.Acad.Sci.U.S.A 2000;97:12222-6.
126. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404:787-90.
127. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;355:253-9.
128. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:23-33.
129. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168-88.
130. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE et al. Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993;16:1376-83.
131. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-9.
132. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-9.
133. Wellmann KF, Volk BW. Renal changes in experimental hypercholesterolemia in normal and in subdiabetic rabbits - II. Long term studies. Lab.Invest. 1971;24:144-54.
134. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33:667-72.
135. Jensen T, Stender S, Deckert T. Abnormalities in plasma concentrations of lipoproteins and fibrinogen in type 1 (insulin-dependent) diabetic patients with increased urinary albumin excretion. Diabetologia 1988;31:142-5.
136. Tarnow L, Rossing P, Nielsen FS, Hansen BV, Dyerberg J, Parving H-H. Increased plasma apolipoprotein(a) levels in IDDM patients with diabetic nephropathy. Diabetes Care 1996;19:1382-7.
137. Keane W, Kasiske BL, O'Donnell MP. Lipids and progressive glomerulosclerosis. Am.J.Nephrol. 1988;8:261-71.
138. Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001;44:1148-54.
139. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int. 2003;64:817-28.
140. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60:219-27.
141. Brenner BM,.Humes HD. Mechanics of glomerular ultrafiltration. N Engl J Med 1977;297:148-54.
142. Mauer SM, Steffes MW, Azar S, Sandberg SK, Brown DM. The effects of Goldblatt hypertension on development of the glomerular lesions of diabetes mellitus in the rat. Diab 1978;27:738-44.
143. Parving H-H, Viberti GC, Keen H, Christiansen JS, Lassen NA. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983;32:943-9.
144. Mathiesen ER, Hilsted J, Feldt-Rasmussen B, Bonde-Petersen F, Christensen NJ, Parving H-H. The effect of metabolic control on hemodynamics in short-term insulin-dependent diabetic patients. Diab 1985; 34:1301-5.
145. Brenner BM, Meyer TW, Hostetter TH. Dietary protein intake and the progressive nature of renal disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 1982;307:652-9.
146. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc.Natl.Acad.Sci.USA 1985;82:5963-7.
147. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
148. Deinum J, Rønn B, Mathiesen ER, Derkx FHM, Hop WCJ, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-10.
149. Deinum J, Tarnow L, van Gool JM, de Bruin RA, Derkx FHM, Schalekamp MADH et al. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrol Dial Transplant 1999;14:1904-11.
150. Shankland SJ,.Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am.J.Physiol Renal Physiol 2000;278:F515-F529.
151. Bonnet F, Cao Z, Cooper ME. Apoptosis and angiotensin II: yet another renal regulatory system? Exp.Nephrol. 2001;9:295-300.
152. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
153. Kastrup J. The diabetic arteriole: The impact of diabetic microangiopathy on microcirculatory control. Dan.Med.Bull. 1988;35:334-45.
154. Cortes P, Zhao X, Riser BL, Narins RG. Role for glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int. 1997;51:57-68.
155. Cortes P, Riser BL, Yee J, Narins RG. Mechanical strain of glomerular mesangial cells in the pathogenesis of glomerulosclerosis: clinical implications. Nephrol Dial Transplant 1999;14:1351-4.
156. Christensen PK, Akram K, Konig KB, Parving H-H. Autoregulation of glomerular filtration rate in patients with type 2 diabetes during isradipine therapy. Diabetes Care 2003;26:156-62.
157. Tarnow L, Rossing P, Gall M-A, Nielsen FS, Parving H-H. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17 (11):1247-51.
158. Viberti GC, Keen H, Wiseman MJ. Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. Br.Med.J. 1987;295:515-7.
159. Fagerudd JA, Tarnow L, Jacobsen P, Stenman S, Nielsen FS, Pettersson-Fernholm KJ et al. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diab 1998;47:439-44.
160. Lurbe E, Redon J, Kesani A, Pascual JM, Tacons J, Alvarez V et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N.Engl.J.Med. 2002;347:797-805.
161. Marre M, Leblanc H, Suarez L, Guyenne T-T, Ménard J, Passa Ph. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. Br.Med.J. 1987;294:1448-52.
162. The Euclid Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787-92.
163. Kvetny J, Gregersen G, Pedersen RS. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. QJM. 2001;94:89-94.
164. Lundbaek K, Jensen VA, Olsen TS, Orskov H, Christensen NJ, Johansen K et al. Growth hormone and diabetic angiopathy. Lancet 1970;2:472.
165. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000;43: 1205-23.
166. Grønbæk H, Volmers P, Bjørn SF, Østerby R, Ørskov H, Flyvbjerg A. Effect of isolated GH and IgF-1 deficiency on long-term renal changes and urinary albumin excretion in streptozotocin diabetic dwarf rats. Am J Physiol 1997;272:E918-E924.
167. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris A, Ørskov H. Octreotide administration in diabetic rats: effects on renal hypertrophy and urinary albumin excretion. Kidney Int. 1992;41:805-12.
168. Flyvbjerg A, Bennett WF, Rasch R, Kopchick JJ, Scarlett JA. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diab 1999;48:377-82.
169. Cummings EA, Sochett EB, Dekker MG, Lawson ML, Daneman D. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diab 1998;47:1341-6.
170. Abboud HE. Growth factors in glomerulonephritis. Kidney Int. 1993;43:252-67.
171. Border WA,.Noble NA. Transforming growth factor beta in tissue fibrosis. N.Engl.J.Med. 1994;331:1286-92.
172. Ziyadeh FN. Mediators of diabetic renal disease: the case for tgf-Beta as the major mediator. J.Am.Soc.Nephrol. 2004;15 Suppl 1:S55-S57.
173. Yamamoto T, Nakamura R, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor b is elevated in human and experimental diabetic nephropathy. Proc.Natl.Acad.Sci.USA 1993;90:1814-8.
174. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc.Natl.Acad.Sci.U.S.A 2000;97:8015-20.
175. Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK et al. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int. 2003;64:451-8.
176. Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003;26:2632-6.
177. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
178. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diab 1999;48:2229-39.
179. Wasada T, Kawahara R, Katsumori K, Naruse M, Omori Y. Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 1998;47:27-30.
180. Hovind P, Tarnow L, Østergaard P, Parving H-H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:S-56-S-61.
181. Burgos R, Simo R, Audi L, Mateo C, Mesa J, Garcia-Ramirez M et al. Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy. Diabetologia 1997;40:1107-9.
182. Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64:1208-13.
183. Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, Parving HH. Low birth weight - a risk factor for development of diabetic nephropathy? Diab 1995;44:1405-7.
184. Rossing P, Tarnow L, Nielsen FS, Boelskifte S, Brenner BM, Parving HH. Short stature and diabetic nephropathy. Br.Med.J. 1995;310:296-7.
185. Borch-Johnsen K. The prognosis of insulin-dependent diabetes mellitus. An epidemiological approach. Dan.Med.Bull. 1989;39:336-49.
186. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br.Med.J. 1982;285:685-8.
187. Parving H-H, Andersen AR, Smidt UM, Hummel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br.Med.J. 1987;294:1443-7.
188. Parving H-H,.Hommel E. Prognosis in diabetic nephropathy. Br.Med.J. 1989;299:230-3.
189. Björck S, Mulec H, Johnsen SAa, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br.Med.J. 1992;304:339-43.
190. Lewis E, Hunsicker L, Bain R, Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
191. Elving LD, Wetzels JFM, van Lier HJJ, de Nobel E, Berden JHM. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia 1994;37:604-9.
192. Rossing P, Hommel E, Smidt UM, Parving H-H. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diab 1993;42:715-9.
193. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. Br.Med.J. 1996;313:591-4.
194. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J et al. Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE Insertion / Deletion genotype? Diabetes Care 2002;26:1501-6.
195. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J.Am.Soc.Nephrol. 2003;14:2843-50.
196. Motulsky AG. Drug reactions enzymes, and biochemical genetics. J.Am.Med.Assoc. 1957;165:835-7.
197. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998;8:283-9.
198. Evans WE,.McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N.Engl.J.Med. 2003;348:538-49.
199. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Use of gene markers to guide antihypertensive therapy. Curr.Hypertens.Rep. 2001;3:410-5.
200. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int. 1989;36:526-36.
201. Alaveras A, Thomas SM, Sagriotis A, Viberti GC. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12:71-4.
202. Parving H-H, Kastrup J, Smidt UM, Andersen AR, Feldt-Rasmussen B, Christiansen JS. Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 1984;27:547-52.
203. Kasiske BL, Kalil R, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118:129-38.
204. Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. Journal of Human Hypertension 1992;6: S23-S36.
205. Hommel E, Parving H-H, Mathiesen ER, Edsberg B, Nielsen MD, Giese J. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. Br.Med.J. 1986;293:466-70.
206. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br.Med.J. 1986;293:471-4.
207. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H. Effects of Losartan on Renal and Cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345: 861-9.
208. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
209. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH et al. Nephropathy in diabetes. Diabetes Care 2004;27 Suppl 1:S79-S83.
210. Fogo AB. Progression and potential regression of glomerulosclerosis. Kidney Int. 2001;59:804-19.
211. Adamczak M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K et al. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats. J.Am.Soc.Nephrol. 2003;14:2833-42.
212. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving H-H. Optimal dose of Candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized crossover study. Diabetes Care 2003;26:150-5.
213. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-62.
214. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am.J.Kidney Dis. 2000;36:646-61.
215. D'Amico G,.Bazzi C. Pathophysiology of proteinuria. Kidney Int. 2003; 63:809-25.
216. Schwartz MM, Bidani AK, Lewis EJ. Glomerular epithelial cell function and pathology following extreme ablation of renal mass. Am.J.Pathol. 1987;126:315-24.
217. Remuzzi G,.Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int. 1990;38:384-94.
218. Russo LM, Bakris GL, Comper WD. Renal handling of albumin: a critical review of basic concepts and perspective. Am.J.Kidney Dis. 2002;39: 899-919.
219. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 1995;123:754-62.
220. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J.Hypertens. 2003;21:1011-53.
221. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J.Hypertens. 2003;21:1983-92.
222. Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes. Diabetes Care 2004;27 Suppl 1:S65-S67.
223. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
224. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349: 1857-63.
225. Walker JD, Bending JJ, Dodds RA, Mattock MB, Murrells TJ, Keen H et al. Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet 1989;ii:1411-5.
226. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving H-H. Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2000;23:1725-30.
227. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR. A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 1981;20:457-61.
228. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H. Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. Br.Med.J. 1983;286:598-602.
229. Berglund J, Lins L-E, Lins P-E. Metabolic and blood pressure monitoring in diabetic renal failure. Acta Med.Scand. 1985;218:401-8.
230. Hasslacher C, Stech W, Wahl P, Ritz E. Blood pressure and metabolic control as risk factors for nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 1985;28:6-11.
231. Nyberg G, Blohmé G, Nordén G. Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 1987; 30:82-6.
232. Parving H-H, Rossing P, Hommel E, Smidt UM. Angiotensin converting enzyme inhibition in diabetic nephropathy: ten years experience. Am J Kidney Diseases 1995;26:99-107.
233. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75.
234. Moorhead JF, El-Nahas M, Chan MK, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982;ii:1309-11.
235. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF. Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ.Res. 1988;62:367-74.
236. Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney Int. 1999;56:S-31-S-36.
237. Hommel E, Andersen P, Gall M-A, Nielsen FS, Jensen BR, Rossing P et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992;35:447-51.
238. Nielsen S, Schmitz O, Møller N, Pørksen N, Klausen IC, Alberti KGMM et al. Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with micro-albuminuria. Diabetologia 1993;36:1079-86.
239. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int. 2001;59:260-9.
240. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361: 2005-16.
241. Pyörälä K, Pedersen TR, Kjekshus J, Færgeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20:614-20.
242. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann.Intern.Med. 2003;138:98-104.
243. Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27 Suppl 1:S68-S71.
244. Breyer JA, Bain P, Evans JK, Nahman NS, Lewis E, Cooper ME et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int. 1996;50:1651-8.
245. Zatz R,. Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am.J.Med. 1986;80:443-53.
246. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
247. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: meta-analysis. Ann Intern Med 1996;124:627-32.
248. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int. 2002;62:220-8.
249. Fouque D, Wang P, Laville M, Boissel JP. Low protein diets delay end-stage renal disease in non-diabetic adults with chronic renal failure. Nephrol.Dial.Transplant. 2000;15:1986-92.
250. Orth SR. Smoking and the kidney. J.Am.Soc.Nephrol. 2002;13:1663-72.
251. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994;17:126-31.
252. Biesenbach G, Janko O, Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 1994;9:1097-102.
253. Hovind P, Rossing P, Tarnow L, Parving HH. Smoking and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care 2003;26:911-6.
254. Klein R, Moss SE, Klein BEK, DeMets DL. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 1989;149:266-72.
255. Moy CS, LaPorte RE, Dorman JS, Songer TJ, Orchard TJ, Kuller LH et al. Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 1990;82:37-43.
256. Breyer JA, Bain RP, Evans JK, Nahman NS, Jr., Lewis EJ, Cooper M et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int. 1996;50:1651-8.
257. Hovind P, Tarnow L, Rossing P, Teerlink T, Stehouwer CD, Emeis JJ et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis. 2001;38:1376-80.
258. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.
259. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998;41:684-93.
260. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Bierhaus A, Henkels M et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8.
261. Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW. Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism 1999;48:1096-101.
262. Neugebauer S, Tarnow L, Stehouwer C, Teerlink T, Baba T, Watanabe T et al. Total plasma homocysteine is associated with hypertension in Type I diabetic patients. Diabetologia 2002;45:1315-24.
263. Friedman AN, Hunsicker LG, Selhub J, Bostom AG. Proteinuria as a predictor of total plasma homocysteine levels in type 2 diabetic nephropathy. Diabetes Care 2002;25:2037-41.
264. Li N, Chen YF, Zou AP. Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 2002;39:443-8.
265. Samuelsson O, Lee DM, Attman PO, Knight-Gibson C, Mullen JK, Larsson R et al. The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression. Nephron 1999;82:306-11.
266. Sarnak MJ, Wang SR, Beck GJ, Kusek JW, Selhub J, Greene T et al. Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. Am.J.Kidney Dis. 2002;40:932-9.
267. Fogo A. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Diseases 2000;35:179-88.
268. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen-activator inhibitor-1 in-vivo - a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int. 1997;51:164-72.
269. Tarnow L, Stehouwer CDA, Emeis JJ, Poirier O, Cambien F, Hansen BV et al. Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic nephropathy. Nephrol Dial Transplant 2000;15:625-30.
270. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int. 2003;63: 1499-507.
271. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J.Am.Soc.Nephrol. 2003; 14: S186-S191.
272. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004;27:765-9.
273. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M et al. A role for uric acid in the progression of renal disease. J.Am.Soc.Nephrol. 2002;13:2888-97.
274. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diab 2000;49:1399-408.
275. Tabaei BP, Al Kassab AS, Ilag LL, Zawacki CM, Herman WH. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2001; 24:1560-6.
276. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N.Engl.J.Med. 2003;348:2285-93.
277. Bojestig M, Karlberg BE, Lindstrom T, Nystrom FH. Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes. Diabetes Care 2001;24:919-24.
278. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F et al. Effects of lisinopril and nifedipine on the progression of overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 1998;21:104-10.
279. The ATLANTIS Study Group. Low-Dose ramipril reduces microalbuminuria in type 1 diabetic patients wihout hypertension. Diabetes Care 2000;23:1823-9.
280. Soto K, Gomez-Garre D, Largo R, Gallego-Delgado J, Tejera N, Catalan MP et al. Tight blood pressure control decreases apoptosis during renal damage. Kidney Int. 2004;65:811-22.
281. Ruggenenti P, Perna A, Benini R, Bertani T, Zoccali C, Maggiore Q et al. In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10:907-1006.
282. Abouna GM, Kremer GD, Daddah SK, Al-Adnani MS, Kumar SA, Kusma G. Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet 1983;ii:1274-6.
283. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H. Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively. Kidney Int. 2001;60:277-83.
284. MacMahon S,. Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001;357:455-62.
285. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the captopril study. Am J Kidney Diseases 1999; 34:308-14.
286. Hovind P, Rossing P, Tarnow L, Toft H, Parving J, Parving HH. Remission of nephrotic-range albuminuria in type 1 diabetic patients. Diabetes Care 2001;24:1972-7.
287. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch.Intern. Med. 1997;157:2413-46.
288. Nuesch R, Schroeder K, Dieterle T, Martina B, Battegay E. Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. Br.Med.J. 2001;323:142-6.
289. Knowles HCJ. Long term juvenile diabetes treated with unmeasured diet. Trans.Assoc.Am.Physicians 1971;84:95-101.
290. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985;28:590-6.
291. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T. Improved survival in patients with diabetic nephropathy. Diabetologia 1989;32:884-6.
292. Stephenson J, Kenny S, Stevens LK, Fuller JH, Lee E, WHO Multinational Study Group. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabetic Med. 1995;12:149-55.
293. de Zeeuw D, Remuzzi G, Parving H-H, Keane W, Zhang Z, Shahinfar S et al. Proteinuria, a therapy target for cardiovascular protection in type 2 diabetic patients with nephropathy. In press, Circulation 2004.
294. Mulec H, Blohmé G, Grände B, Björck S. The effect of metabolic control on rate of decline in renal function in insulin-dependent diabetes mellitus with overt diabetic nephropathy. Nephrol Dial Transplant 1998;13:651-5.